
|Articles|August 1, 2001
- Pharmaceutical Executive-08-01-2001
- Volume 0
- Issue 0
Science-Driven Marketing
Author(s)Wayne Koberstein
That marketing should begin early in product development has become a truism in the pharma industry. But as a statement on its own, it sheds little light. What does it mean to begin? At what point do marketers insert themselves into the process? To what end do they enter where once only scientists trod? And, the ultimate question—which the truism fails to answer—how might their intrusion affect the lives of patients, in trial or thereafter?
Advertisement
Articles in this issue
over 24 years ago
Decision Making at Digital Speedover 24 years ago
Mergers: Big Pharma Shrinks Someover 24 years ago
Generics: Streamline and Stimulateover 24 years ago
Grace Under Fireover 24 years ago
Get Ready to Merge or Divergeover 24 years ago
Pharma's Quantum ShuffleNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
From Evidence to Access: How Real-World Data Delivers for Patients
2
Pharma Companies Raise List Prices, Including 16 That Had Agreements to Lower Prices with Trump Administration: Report
3
Tariff Uncertainty Drives Short-Term Manufacturing Surge as Global Pharmaceuticals Enter Fragmented Growth Phase: Report
4
WHO Finalizes United States’ Withdrawal from Organization: Report
5



